CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Clearside Biomedical, Inc. - CLSD CFD

    0.8573
    2.39%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.0153
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Clearside Biomedical Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 0.8373
    Open* 0.8373
    1-Year Change* -21.01%
    Day's Range* 0.8373 - 0.8633
    52 wk Range 0.85-1.85
    Average Volume (10 days) 89.50K
    Average Volume (3 months) 2.60M
    Market Cap 52.73M
    P/E Ratio -100.00K
    Shares Outstanding 62.03M
    Revenue 1.62M
    EPS -0.59
    Dividend (Yield %) N/A
    Beta 2.17
    Next Earnings Date Nov 6, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 29, 2023 0.8573 0.0200 2.39% 0.8373 0.8643 0.8373
    Sep 28, 2023 0.8373 0.0000 0.00% 0.8373 0.8574 0.8333
    Sep 27, 2023 0.8573 0.0100 1.18% 0.8473 0.8698 0.8473
    Sep 26, 2023 0.8573 0.0150 1.78% 0.8423 0.8655 0.8423
    Sep 25, 2023 0.8474 0.0101 1.21% 0.8373 0.8570 0.8373
    Sep 22, 2023 0.8525 0.0352 4.31% 0.8173 0.8543 0.8173
    Sep 21, 2023 0.8273 0.0100 1.22% 0.8173 0.8283 0.8173
    Sep 20, 2023 0.8273 0.0000 0.00% 0.8273 0.8463 0.8273
    Sep 19, 2023 0.8279 0.0106 1.30% 0.8173 0.8470 0.8173
    Sep 18, 2023 0.8298 0.0025 0.30% 0.8273 0.8473 0.8223
    Sep 15, 2023 0.8473 0.0000 0.00% 0.8473 0.8642 0.8373
    Sep 14, 2023 0.8430 -0.0043 -0.51% 0.8473 0.8683 0.8405
    Sep 13, 2023 0.8496 -0.0097 -1.13% 0.8593 0.8673 0.8473
    Sep 12, 2023 0.8537 -0.0136 -1.57% 0.8673 0.8773 0.8503
    Sep 11, 2023 0.8673 0.0050 0.58% 0.8623 0.8873 0.8504
    Sep 8, 2023 0.8533 0.0060 0.71% 0.8473 0.8673 0.8323
    Sep 7, 2023 0.8473 0.0000 0.00% 0.8473 0.8548 0.8473
    Sep 6, 2023 0.8499 -0.0374 -4.22% 0.8873 0.8973 0.8473
    Sep 5, 2023 0.8593 -0.0394 -4.38% 0.8987 0.9273 0.8473
    Sep 1, 2023 0.9073 0.0100 1.11% 0.8973 0.9283 0.8973

    Clearside Biomedical, Inc. Events

    Time (UTC) Country Event
    Monday, November 6, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q3 2023 Clearside Biomedical Inc Earnings Release
    Q3 2023 Clearside Biomedical Inc Earnings Release

    Forecast

    -

    Previous

    -
    Thursday, March 7, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 Clearside Biomedical Inc Earnings Release
    Q4 2023 Clearside Biomedical Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 1.327 29.575 7.894 2.173 0.03
    Revenue 1.327 29.575 7.894 2.173 0.03
    Total Operating Expense 30.935 29.199 25.829 32.477 82.975
    Selling/General/Admin. Expenses, Total 11.77 11.665 10.756 16.819 14.684
    Research & Development 19.63 18.537 15.073 15.658 68.291
    Operating Income -29.608 0.376 -17.935 -30.304 -82.945
    Other, Net -3.339 0 -0.275 -0.466 0.127
    Net Income Before Taxes -32.947 0.376 -18.21 -30.77 -82.818
    Net Income After Taxes -32.947 0.376 -18.21 -30.77 -82.818
    Net Income Before Extra. Items -32.947 0.376 -18.21 -30.77 -82.818
    Net Income -32.947 0.376 -18.21 -30.77 -82.818
    Income Available to Common Excl. Extra. Items -32.947 0.376 -18.21 -30.77 -82.818
    Income Available to Common Incl. Extra. Items -32.947 0.376 -18.21 -30.77 -82.818
    Diluted Net Income -32.947 0.376 -18.21 -30.77 -82.818
    Diluted Weighted Average Shares 60.2049 59.9066 46.5065 38.1708 30.7336
    Diluted EPS Excluding Extraordinary Items -0.54725 0.00628 -0.39156 -0.80611 -2.69471
    Diluted Normalized EPS -0.55836 -0.01047 -0.39156 -0.80611 -2.69471
    Total Extraordinary Items
    Unusual Expense (Income) -0.669 -1.003
    Cost of Revenue, Total 0.204
    Gross Profit 1.123
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 1.018 0.004 0.33 0.266 0.384
    Revenue 1.018 0.004 0.33 0.266 0.384
    Total Operating Expense 7.83 7.117 7.951 6.796 8.197
    Selling/General/Admin. Expenses, Total 3.127 3.158 3.169 2.353 2.791
    Research & Development 4.948 4.451 5.027 4.637 5.43
    Unusual Expense (Income) -0.458 -0.492 -0.449 -0.194 -0.024
    Operating Income -6.812 -7.113 -7.621 -6.53 -7.813
    Other, Net -2.294 -2.167 -2.042 -1.297
    Net Income Before Taxes -9.106 -9.28 -9.663 -7.827 -7.813
    Net Income After Taxes -9.106 -9.28 -9.663 -7.827 -7.813
    Net Income Before Extra. Items -9.106 -9.28 -9.663 -7.827 -7.813
    Net Income -9.106 -9.28 -9.663 -7.827 -7.813
    Income Available to Common Excl. Extra. Items -9.106 -9.28 -9.663 -7.827 -7.813
    Income Available to Common Incl. Extra. Items -9.106 -9.28 -9.663 -7.827 -7.813
    Diluted Net Income -9.106 -9.28 -9.663 -7.827 -7.813
    Diluted Weighted Average Shares 61.6545 61.1695 60.415 60.1885 60.1503
    Diluted EPS Excluding Extraordinary Items -0.14769 -0.15171 -0.15994 -0.13004 -0.12989
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.15512 -0.15975 -0.16738 -0.13326 -0.13029
    Cost of Revenue, Total 0.213 0.204
    Gross Profit 0.805 0.126
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 49.401 42.136 18.118 25.219 42.944
    Cash and Short Term Investments 48.258 30.436 17.287 22.595 40.878
    Cash & Equivalents 48.258 30.436 17.287 22.595 8.043
    Short Term Investments 0 32.835
    Prepaid Expenses 0.704 0.921 0.722 1.139 2.049
    Other Current Assets, Total 0.439 0.779 0.109 1.485 0.017
    Total Assets 51.303 42.903 19.322 26.776 44.12
    Property/Plant/Equipment, Total - Net 1.872 0.607 0.944 1.197 0.79
    Property/Plant/Equipment, Total - Gross 2.725 1.562 1.721 1.794 1.199
    Accumulated Depreciation, Total -0.853 -0.955 -0.777 -0.597 -0.409
    Other Long Term Assets, Total 0.03 0.16 0.26 0.36 0.386
    Total Current Liabilities 5.783 4.64 9.943 10.903 10.476
    Accounts Payable 1.05 0.941 1.997 1.28 6.869
    Accrued Expenses 4.528 3.699 1.955 3.29 2.923
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.205 0 5 5 0.128
    Total Liabilities 40.696 4.928 10.559 15.619 20.5
    Total Long Term Debt 0 0 0 3.819 9.419
    Long Term Debt 0 3.819 9.419
    Other Liabilities, Total 34.913 0.288 0.616 0.897 0.605
    Total Equity 10.607 37.975 8.763 11.157 23.62
    Redeemable Preferred Stock 0 0
    Common Stock 0.061 0.06 0.052 0.044 0.032
    Additional Paid-In Capital 298.984 293.406 264.578 248.77 230.475
    Retained Earnings (Accumulated Deficit) -288.438 -255.491 -255.867 -237.657 -206.887
    Other Equity, Total 0
    Total Liabilities & Shareholders’ Equity 51.303 42.903 19.322 26.776 44.12
    Total Common Shares Outstanding 60.6398 59.7229 51.8609 44.4134 32.1192
    Current Port. of LT Debt/Capital Leases 0 0.991 1.333 0.556
    Total Receivables, Net 0 10
    Accounts Receivable - Trade, Net 0 10
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 42.567 49.401 54.862 29.989 35.274
    Cash and Short Term Investments 41.419 48.258 53.381 29.033 34.372
    Cash & Equivalents 41.419 48.258 53.381 29.033 34.372
    Prepaid Expenses 0.762 0.704 1.047 0.439 0.563
    Other Current Assets, Total 0.386 0.439 0.311 0.394 0.339
    Total Assets 44.695 51.303 55.685 30.746 36.059
    Property/Plant/Equipment, Total - Net 2.098 1.872 0.663 0.597 0.625
    Property/Plant/Equipment, Total - Gross 2.966 2.725 1.741 1.636 1.626
    Accumulated Depreciation, Total -0.868 -0.853 -1.078 -1.039 -1.001
    Other Long Term Assets, Total 0.03 0.03 0.16 0.16 0.16
    Total Current Liabilities 4.984 5.783 5.204 5.393 4.156
    Accounts Payable 1.594 1.05 1.739 2.644 1.396
    Accrued Expenses 3.11 4.528 3.352 2.749 2.562
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases
    Other Current Liabilities, Total 0.28 0.205 0.113 0.198
    Total Liabilities 41.995 40.696 37.139 5.498 4.356
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 37.011 34.913 31.935 0.105 0.2
    Total Equity 2.7 10.607 18.546 25.248 31.703
    Common Stock 0.061 0.061 0.06 0.06 0.06
    Additional Paid-In Capital 300.357 298.984 297.261 296.136 294.778
    Retained Earnings (Accumulated Deficit) -297.718 -288.438 -278.775 -270.948 -263.135
    Total Liabilities & Shareholders’ Equity 44.695 51.303 55.685 30.746 36.059
    Total Common Shares Outstanding 61.3643 60.6398 60.1907 60.1504 60.1476
    Redeemable Preferred Stock
    Total Receivables, Net 0 0.123 0.123 0
    Accounts Receivable - Trade, Net 0 0.123 0.123 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -32.947 0.376 -18.21 -30.77 -82.818
    Cash From Operating Activities -13.365 -10.733 -13.12 -27.068 -79.2
    Cash From Operating Activities 0.145 0.178 0.18 0.211 0.189
    Non-Cash Items 8.201 4.056 3.788 4.79 4.303
    Cash Interest Paid 0 0 0.524 0.843 0.751
    Changes in Working Capital 11.236 -15.343 1.122 -1.299 -0.874
    Cash From Investing Activities -0.246 0 -0.055 32.925 -3.76
    Capital Expenditures -0.246 0 -0.055 -0.025 -0.088
    Other Investing Cash Flow Items, Total 0 32.95 -3.672
    Cash From Financing Activities 31.333 23.782 7.867 8.695 81.779
    Issuance (Retirement) of Stock, Net 0.695 23.782 12.216 13.695 80.079
    Issuance (Retirement) of Debt, Net 0 0 -4.349 -5 1.7
    Net Change in Cash 17.722 13.049 -5.308 14.552 -1.181
    Financing Cash Flow Items 30.638
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -9.28 -32.947 -23.284 -15.457 -7.644
    Cash From Operating Activities -7.216 -13.365 -7.758 -1.572 3.871
    Cash From Operating Activities 0.015 0.145 0.123 0.084 0.046
    Non-Cash Items 3.208 8.201 5.032 2.661 1.307
    Changes in Working Capital -1.159 11.236 10.371 11.14 10.162
    Cash From Investing Activities -0.115 -0.246 -0.155 0 0
    Capital Expenditures -0.115 -0.246 -0.155
    Cash From Financing Activities 0.332 31.333 30.758 0.069 0.065
    Issuance (Retirement) of Stock, Net 0.332 0.695 0.12 0.069 0.065
    Net Change in Cash -6.999 17.722 22.845 -1.503 3.936
    Issuance (Retirement) of Debt, Net 0
    Other Investing Cash Flow Items, Total 0 0
    Financing Cash Flow Items 30.638 30.638

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Clearside Biomedical, Inc. Company profile

    About Clearside Biomedical Inc

    Clearside Biomedical, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Its proprietary suprachoroidal space (SCS) microinjector targeting SCS offers access to the macula, retina and choroid where sight-threatening disease often occurs. The SCS injection platform is an inherently flexible, in-office, non-surgical procedure intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations. The Company’s suprachoroidal injection platform is a patented approach for delivering pharmacotherapy to the back of the eye through SCS. The Company’s lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Clearside Biomedical Inc revenues increased from $7.9M to $29.6M. Net income totaled $376K vs. loss of $18.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Other expense decrease from $275K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.39 to $0.01.

    Industry: Bio Therapeutic Drugs

    900 North Point Parkway
    Suite 200
    ALPHARETTA
    GEORGIA 30005
    US

    Income Statement

    • Annual
    • Quarterly

    News

    How to Trade The Triple Top

    Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

    14:13, 27 September 2023
    USA flag on the background of stock charts. Financial system in USA

    Q4 lookahead: US indices starting to show signs of trouble?

    US indices start to draw attention as traders focus on the outlook for Q4.

    07:20, 27 September 2023

    USD/JPY Climbs Towards Key Highs

    USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

    11:32, 26 September 2023

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    People also watch

    XRP/USD

    0.52 Price
    -3.040% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    Oil - Crude

    90.04 Price
    -1.230% 1D Chg, %
    Long position overnight fee 0.0661%
    Short position overnight fee -0.0881%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    ETH/USD

    1,680.64 Price
    +0.630% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    BTC/USD

    27,053.60 Price
    +0.390% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading